![]() |
市場調查報告書
商品編碼
2176486
人工智慧驅動的睡眠呼吸中止症檢測設備市場預測至2034年——全球產品類型、睡眠呼吸中止症類型、技術、應用、最終用戶和地區分析AI-Enabled Sleep Apnea Detection Devices Market Forecasts to 2034 - Global Analysis By Product Type, Sleep Apnea Type, Technology, Application, End User and By Geography |
||||||
根據 Stratistics MRC 的數據,全球人工智慧驅動的睡眠呼吸中止症檢測設備市場預計將在 2026 年達到 18 億美元,並在預測期內以 19.3% 的複合年成長率成長,到 2034 年達到 74 億美元。
人工智慧驅動的睡眠呼吸中止症檢測設備市場涵蓋智慧穿戴式感測器、攜帶式診斷設備、非接觸式監測技術以及整合人工智慧的睡眠評估系統,旨在識別睡眠阻塞型睡眠呼吸中止症、居家診斷需求的成長以及數位醫療技術的廣泛應用正在推動市場成長。生理訊號分析、機器學習和自動睡眠評分技術的進步正在提升檢測能力。對價格親民的睡眠診斷技術投入的增加也創造了更多機會。
睡眠呼吸中止症的盛行率不斷上升,以及對易於取得的診斷解決方案的需求日益成長。
睡眠呼吸中止症盛行率的不斷上升以及對便捷診斷方案日益成長的需求正在推動市場成長。人們對睡眠呼吸障礙及其與心血管和代謝併發症之間關聯的認知不斷提高,加速了早期篩檢的發展。傳統的院內睡眠檢測費用昂貴、資源有限且等待時間長。人工智慧設備支援對呼吸模式、血氧飽和度和睡眠相關生理訊號進行自動分析。攜帶式居家檢測和穿戴式監測技術的普及正在改善診斷的可及性。醫療保健的日益數位化進一步推動了市場需求。
基於人工智慧的睡眠呼吸中止症檢測在臨床準確性和監管方面的限制。
人工智慧驅動的睡眠呼吸中止症檢測在臨床準確性方面的局限性以及監管方面的挑戰阻礙了市場成長。穿戴式和非接觸式裝置可能因身體運動、感測器放置位置以及個體睡眠模式差異等因素而導致結果不一致。有些消費級技術僅提供篩檢指標,而非臨床檢驗的診斷。設備效能和演算法訓練資料集的差異也使結果解讀變得複雜。法規核准、保險覆蓋範圍限制和資料隱私要求是進一步的障礙。醫療機構可能要求在開始治療前進行睡眠測試以獲得明確診斷。
擴展家庭睡眠診斷和人工智慧整合穿戴監測平台
居家睡眠診斷和人工智慧整合穿戴監測平台的普及帶來了巨大的成長機會。醫療科技公司正在開發集呼吸監測、血氧飽和度評估和智慧睡眠模式分析於一體的緊湊型設備。對便利偵測日益成長的需求推動了這些裝置與智慧型手機、雲端平台和遠端醫療服務的整合。多模態生理感測和自動睡眠評分技術的進步正在改善診斷流程。睡眠診所、穿戴式科技製造商和數位醫療服務提供者之間的合作有望加速這些技術的商業化和普及應用。
人們對該演算法的可靠性以及與現有睡眠多導圖系統的競爭表示擔憂。
演算法可靠性以及與現有多導睡眠圖系統的競爭問題,對市場發展構成重大挑戰。人工智慧驅動的睡眠呼吸中止症檢測依賴於精確的生理測量、代表性的訓練資料集和檢驗的臨床演算法。假陰性篩檢結果可能導致診斷延誤,而假陽性觀察可能導致不必要的檢查增加。現有的多導睡眠圖仍然是全面睡眠評估的關鍵標準。網路安全風險和敏感健康資料的處理也是需要關注的問題。不斷變化的醫療設備法規以及消費級穿戴裝置之間的競爭也可能進一步影響市場接受度。
新冠疫情導致睡眠醫學服務中斷,檢測延遲、預約受限、診斷機構服務減少。這些挑戰促使人們對攜帶式居家睡眠呼吸中止症檢測、遠端監測和數位化診斷流程產生了濃厚的興趣。醫療服務提供者探索利用連網型設備和自動化分析技術,在傳統檢測機構之外進行睡眠評估。然而,供應鏈中斷和選擇性診斷活動的減少影響了設備的普及。遠端醫療將繼續推動市場發展。
在預測期內,攜帶式家用睡眠呼吸中止症檢測設備細分市場預計將佔據最大的市場佔有率。
在預測期內,攜帶式家用睡眠呼吸中止監測設備預計將佔據最大的市場佔有率,這主要得益於消費者對便利、經濟高效且具有臨床支持的睡眠呼吸中止症評估日益成長的需求。這些設備無需在專業的睡眠檢測機構內即可監測特定的呼吸和生理參數,有助於識別需要進一步評估或治療的患者。人工智慧訊號分析和自動報告功能的整合正在提高診斷效率。遠端醫療服務的擴展以及符合條件的家用檢測可獲得保險報銷,正在推動此類設備的普及。此外,人們對睡眠呼吸中止症的認知不斷提高,也進一步促進了該細分市場的成長。
在預測期內,多模態生理訊號分析領域預計將呈現最高的複合年成長率。
在預測期內,由於使用多種生理指標進行全面睡眠評估的需求不斷成長,多模態生理訊號分析領域預計將呈現最高的成長率。這些系統透過結合呼吸訊號、血氧飽和度、心率變異性、運動模式和其他測量數據,提高了睡眠呼吸障礙檢測的準確性。與穿戴式感測器和攜帶式診斷平台的整合技術的進步正在推動創新。雖然機器學習和資料融合技術的進步可能會加速其應用,但臨床檢驗對於診斷應用仍然至關重要。
在預測期內,北美預計將佔據最大的市場佔有率,這得益於其完善的睡眠醫學基礎設施、對醫療技術的巨額投資以及家用睡眠呼吸中止症檢測的日益普及。人工智慧驅動的睡眠評估正透過攜帶式診斷設備、數位健康平台和遠端患者監護服務在美國和加拿大蓬勃發展。人們對阻塞型睡眠呼吸中止症的認知不斷提高,以及對便利診斷途徑的需求日益成長,正在推動該地區的市場發展。睡眠診所、醫療設備製造商和醫療保健提供者之間的合作進一步鞏固了北美的市場地位。
在預測期內,亞太地區預計將呈現最高的複合年成長率,這主要得益於醫療基礎設施的不斷完善、人們對睡眠障礙認知的提高以及互聯診斷技術的廣泛應用。睡眠醫療服務和數位健康舉措正在中國、印度、日本、韓國和澳洲蓬勃發展。不斷成長的醫療支出和對價格合理的居家檢測需求的增加正在推動技術的普及應用。穿戴式感測器、基於智慧型手機的監測以及人工智慧驅動的睡眠分析技術的進步預計將加速該地區的市場成長。
According to Stratistics MRC, the Global AI-Enabled Sleep Apnea Detection Devices Market is accounted for $1.8 billion in 2026 and is expected to reach $7.4 billion by 2034 growing at a CAGR of 19.3% during the forecast period. The AI-Enabled Sleep Apnea Detection Devices Market encompasses intelligent wearable sensors, portable diagnostic equipment, contactless monitoring technologies, and AI-integrated sleep assessment systems designed to identify sleep-disordered breathing. Increasing prevalence of obstructive sleep apnea, growing demand for home-based diagnosis, and expanding adoption of digital healthcare technologies are supporting market growth. Advancements in physiological signal analysis, machine learning, and automated sleep scoring improve detection capabilities. Growing investment in accessible sleep diagnostics creates additional opportunities.
Increasing prevalence of sleep apnea and demand for accessible diagnostic solutions
Increasing prevalence of sleep apnea and demand for accessible diagnostic solutions is driving market growth. Growing awareness of sleep-disordered breathing and its association with cardiovascular and metabolic complications encourages earlier screening. Conventional laboratory-based sleep studies may involve high costs, limited availability, and lengthy waiting periods. AI-enabled devices support automated analysis of respiratory patterns, oxygen saturation, and sleep-related physiological signals. Expanding adoption of portable home testing and wearable monitoring technologies improves diagnostic accessibility. Increasing healthcare digitalization further strengthens demand.
Clinical accuracy limitations and regulatory challenges in AI-based sleep apnea detection
Clinical accuracy limitations and regulatory challenges in AI-based sleep apnea detection restrain market growth. Wearable and contactless devices may produce inconsistent results due to movement artifacts, sensor placement, and variations in individual sleep patterns. Some consumer technologies provide screening indications rather than clinically validated diagnoses. Differences in device performance and algorithm training datasets complicate interpretation. Regulatory approval, reimbursement limitations, and data privacy requirements create additional barriers. Healthcare providers may require confirmatory sleep studies before initiating treatment.
Expansion of home-based sleep diagnostics and AI-integrated wearable monitoring platforms
Expansion of home-based sleep diagnostics and AI-integrated wearable monitoring platforms presents significant growth opportunities. Healthcare technology companies are developing compact devices that combine respiratory monitoring, oxygen saturation assessment, and intelligent sleep pattern analysis. Growing demand for convenient testing encourages integration with smartphones, cloud platforms, and telehealth services. Advancements in multimodal physiological sensing and automated sleep scoring improve diagnostic workflows. Partnerships among sleep clinics, wearable technology manufacturers, and digital health providers are expected to accelerate commercialization and adoption.
Algorithm reliability concerns and competition from established polysomnography systems
Algorithm reliability concerns and competition from established polysomnography systems pose significant challenges to market development. AI-enabled sleep apnea detection depends on accurate physiological measurements, representative training datasets, and validated clinical algorithms. False-negative screening results may delay diagnosis, while false-positive findings can increase unnecessary testing. Established polysomnography remains an important reference standard for comprehensive sleep assessment. Cybersecurity risks and sensitive health data handling create additional concerns. Evolving medical device regulations and competition among consumer wearables may further influence market adoption.
The COVID-19 pandemic disrupted sleep medicine services through postponed laboratory studies, restricted clinical appointments, and reduced access to diagnostic facilities. These challenges increased interest in portable home sleep apnea testing, remote monitoring, and digital diagnostic workflows. Healthcare providers explored connected devices and automated analysis to maintain access to sleep assessments outside conventional laboratories. However, supply chain disruptions and reduced elective diagnostic activity affected device deployment. Post-pandemic expansion of telehealth and home-based diagnostic services continues to support market development.
The portable home sleep apnea testing devices segment is expected to be the largest during the forecast period
The portable home sleep apnea testing devices segment is expected to account for the largest market share during the forecast period due to increasing demand for convenient, cost-effective, and clinically supported sleep apnea assessment. These devices monitor selected respiratory and physiological parameters outside specialized sleep laboratories, helping identify patients requiring further evaluation or treatment. Growing integration of AI-based signal analysis and automated reporting improves diagnostic efficiency. Expanding telehealth services and reimbursement support for eligible home testing encourage adoption. Increasing sleep apnea awareness further strengthens segment growth.
The multimodal physiological signal analysis segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the multimodal physiological signal analysis segment is predicted to witness the highest growth rate due to increasing demand for comprehensive sleep assessment using multiple physiological indicators. These systems combine respiratory signals, oxygen saturation, heart rate variability, movement patterns, and other measurements to improve detection of sleep-disordered breathing. Growing integration with wearable sensors and portable diagnostic platforms encourages innovation. Advancements in machine learning and data fusion could accelerate adoption, although clinical validation remains essential for diagnostic applications.
During the forecast period, North America is expected to hold the largest market share due to established sleep medicine infrastructure, significant healthcare technology investment, and growing adoption of home sleep apnea testing. The United States and Canada are advancing AI-enabled sleep assessment through portable diagnostic devices, digital health platforms, and remote patient monitoring services. Increasing awareness of obstructive sleep apnea and demand for convenient diagnostic pathways encourage regional market development. Collaboration among sleep clinics, medical device manufacturers, and healthcare providers further strengthens North America's position.
Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding healthcare infrastructure, increasing sleep disorder awareness, and growing adoption of connected diagnostic technologies. China, India, Japan, South Korea, and Australia are advancing sleep medicine services and digital health initiatives. Increasing healthcare expenditure and demand for affordable home-based testing encourage technology adoption. Improvements in wearable sensors, smartphone-enabled monitoring, and AI-assisted sleep analysis are expected to accelerate regional market growth.
Key players in the market
Some of the key players in the AI-Enabled Sleep Apnea Detection Devices Market include ResMed Inc., Koninklijke Philips N.V., ZOLL Medical Corporation (Itamar Medical), Nox Medical, Compumedics Limited, Nihon Kohden Corporation, EnsoData, Inc., Onera Health B.V., Acurable Ltd., Sunrise, Wesper, Sleepiz AG, Huxley Medical, Inc., PranaQ Pte. Ltd., SleepImage, Beacon Biosignals, Inc., SOMNOmedics GmbH, and Samsung Electronics Co., Ltd.
In October 2026, Samsung Electronics Co., Ltd. announced regulatory approval in South Korea for an enhanced sleep apnea monitoring feature on compatible Galaxy wearables. The updated AI-based system analyzes breathing disturbances and provides more detailed risk information, supporting earlier identification of potential sleep-disordered breathing. The feature is intended for screening and does not replace professional diagnosis.
In September 2026, ResMed Inc. highlighted new research at the European Respiratory Society Congress examining sleep apnea care across the treatment journey. The initiative reflects growing industry attention to improved screening, patient identification, and personalized respiratory care, supporting the development of connected sleep health technologies.
In June 2026, Nox Medical highlighted advancements in AI-assisted sleep diagnostics through technologies designed to improve sleep staging, respiratory event analysis, and identification of obstructive sleep apnea. Its approach emphasizes more detailed physiological assessment using home sleep testing data, supporting improved clinical interpretation and personalized sleep care.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.